SCHEMBL1745155

SCHEMBL1745155

OCc1ccc(CSc2nc(-c3ccccc3)cs2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.57
HTT P42858 1/20 0.57
TSHR P16473 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
TP53 P04637 2/20 0.55
MCL1 Q07820 1/20 0.55
HTR1A P08908 1/20 0.55
HTR2A P28223 1/20 0.55
HTR7 P34969 1/20 0.55
NPC1 O15118 3/20 0.52
TDP1 Q9NUW8 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
ALDH1A1 P00352 4/20 0.50
HPGD P15428 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746713 0.79 TSHR (0.71) RAB9ATSHRL3MBTL1TP53MCL1
SCHEMBL18169169 0.76 RAB9A (0.69) RAB9AHTTTSHRL3MBTL1TP53
SCHEMBL7366759 0.75 HTR1A (0.60) RAB9AHTTTSHRL3MBTL1TP53
SCHEMBL1745596 0.74 FFAR1 (0.60) TSHRL3MBTL1TP53MCL1
SCHEMBL1540756 0.74 HTR1A (0.67) RAB9AHTTTSHRL3MBTL1TP53
SCHEMBL10613520 0.73 RAB9A (0.60) RAB9AHTTTP53HTR1AHTR2A
SCHEMBL7183029 0.73 PTPN1 (0.48) RAB9AHTTTSHRL3MBTL1TP53
SCHEMBL12599117 0.73 HTR1A (0.74) RAB9AHTTTSHRL3MBTL1TP53
SCHEMBL8044700 0.71 RAB9A (0.48) RAB9AHTTTSHRL3MBTL1TP53
SCHEMBL9334806 0.71 RAB9A (0.57) RAB9AHTTTP53HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
CN-1735408-A Receptor function controlling agent TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-02-15 CN disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR RAB9A 2029/4885HTT 3142/4885TSHR 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.